Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.

Ntellas P, Park H, Culm K, Lee J, Youssoufian H, Mockbee C, Uhlik M, Benjamin L, Chau I

Open source

DOI: 10.3390/curroncol33060319
Published: 2026 May 28
Container: Current oncology (Toronto, Ont.)
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/curroncol33060319,
  title = {Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.},
  author = {Ntellas P and Park H and Culm K and Lee J and Youssoufian H and Mockbee C and Uhlik M and Benjamin L and Chau I},
  year = {2026},
  journal = {Current oncology (Toronto, Ont.)},
  doi = {10.3390/curroncol33060319},
  url = {https://doi.org/10.3390/curroncol33060319}
}

RIS

TY  - JOUR
TI  - Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.
AU  - Ntellas P
AU  - Park H
AU  - Culm K
AU  - Lee J
AU  - Youssoufian H
AU  - Mockbee C
AU  - Uhlik M
AU  - Benjamin L
AU  - Chau I
PY  - 2026
JO  - Current oncology (Toronto, Ont.)
DO  - 10.3390/curroncol33060319
UR  - https://doi.org/10.3390/curroncol33060319
ER  -

APA

P, N., H, P., K, C., J, L., H, Y., C, M., M, U., L, B., & I, C. (2026). Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.. Current oncology (Toronto, Ont.). https://doi.org/10.3390/curroncol33060319

Source records

pubmed · retrieved 2026-09-26T08:45:26.853Z
europe-pmc · retrieved 2026-09-26T08:45:26.863Z
doaj · retrieved 2026-09-26T08:45:26.854Z